ExpreS2ion Biotech Holding AB (EXPRS2) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-1.06x
ExpreS2ion Biotech Holding AB (EXPRS2) has a Cash Flow-to-Debt Ratio of -1.06x as of March 2026, meaning its operating cash flow of Skr-25.49 Million could theoretically repay -1% of its total liabilities (Skr23.98 Million) in one year. See EXPRS2 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.06x
Operating CF / Total Liabilities
Operating Cash Flow
Skr-25.49 Million
SEK
Total Liabilities
Skr23.98 Million
SEK
Data as of
Mar 2026
Most recent filing
ExpreS2ion Biotech Holding AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for ExpreS2ion Biotech Holding AB across 10 annual periods. For the full cash flow conversion analysis, see ExpreS2ion Biotech Holding AB cash flow conversion.
Annual Cash Flow-to-Debt Ratio for ExpreS2ion Biotech Holding AB (2016–2025)
Year-by-year debt coverage analysis for ExpreS2ion Biotech Holding AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.39x | Skr-40.90 Million | Skr29.42 Million | ▼ -64.4% |
| 2024 | -0.85x | Skr-33.93 Million | Skr40.11 Million | ▲ +88.8% |
| 2023 | -7.57x | Skr-100.89 Million | Skr13.33 Million | ▼ -158.6% |
| 2022 | -2.93x | Skr-99.61 Million | Skr34.04 Million | ▲ +25.6% |
| 2021 | -3.93x | Skr-45.65 Million | Skr11.61 Million | ▼ -425.9% |
| 2020 | -0.75x | Skr-18.18 Million | Skr24.31 Million | ▼ -16.6% |
| 2019 | -0.64x | Skr-12.69 Million | Skr19.79 Million | ▲ +37.0% |
| 2018 | -1.02x | Skr-12.88 Million | Skr12.65 Million | ▼ -24.1% |
| 2017 | -0.82x | Skr-8.61 Million | Skr10.50 Million | ▼ -37.1% |
| 2016 | -0.60x | Skr-7.02 Million | Skr11.73 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.